 |
      
|
|
|
|
|
|||||
|
|
December 8, 2003
Neurochem's Annual General and Special Shareholders' meeting and media briefing session. Date Book
What About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics for
neurological disorders. The Company's staged pipeline of proprietary, disease-modifying, oral
products addresses critical unmet medical needs. Fibrillex™, designated an orphan drug, is in
a Phase II/III clinical trial for AA amyloidosis. Alzhemed™ has completed a Phase II clinical
trial. Cerebril™ is in a Phase II trial for the prevention of hemorrhagic stroke caused by
cerebral amyloid angiopathy. Neurochem is also developing a product for the potential treatment of
epileptic seizures induced by traumatic brain injury. For additional information on Neurochem,
please visit our website at: (www.neurochem.com).
Certain statements contained in this news release, other than statements of fact that are
independently verifiable at the date hereof, may constitute forward-looking statements. Such
statements, based as they are on the current expectations of management, inherently involve
numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem's control.
Such risks include but are not limited to: the impact of general economic conditions, general
conditions in the pharmaceutical industry, changes in the regulatory environment in the
jurisdictions in which Neurochem does business, stock market volatility, fluctuations in costs,
and changes to the competitive environment due to consolidation as well as other risks included in
public filings of Neurochem. Consequently, actual future results may differ materially from the
anticipated results expressed in the forward-looking statements. The reader should not place
undue reliance on the forward-looking statements included in this news release.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
